Infectious disease specialists are highlighting the growing clinical challenge of managing invasive mold infections, particularly mucormycosis and invasive aspergillosis — two conditions that can be life-threatening in immunocompromised patients. A recent review in Infectious Disease Special Edition examines new, established, and combination antifungal treatment approaches including liposomal amphotericin B and isavuconazole.
The discussion reflects increasing recognition within the medical community that mold-related health impacts extend beyond allergic responses. Invasive fungal infections represent the most acute end of a spectrum that also includes chronic inflammatory responses in immunocompetent individuals exposed to mold in environmental settings.